Navigation Links
Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients
Date:10/7/2008

the 3-mg targeted dose. Typical changes in FEV1 over a 24-hour period were less than or equal to 10%.

Aerovant is a recombinant human IL-4 variant that is a potent inhibitor of both the IL-4 and IL-13 receptors. Aerovance acquired the worldwide rights to the drug candidate when the company was formed as a spin-out of Bayer Pharmaceuticals Corporation in 2004.

Aerovance Inc. is a Berkeley, Calif.-based biopharmaceutical company focused on the development and commercialization of breakthrough therapies for the treatment of respiratory and inflammatory diseases. For more information, visit http://www.aerovance.com.

Contact: Andreas Marathovouniotis or David Schull

Russo Partners

212-845-4235 or 212-845-4271

andreas.marathis@russopartnersllc.com

david.schull@russopartnersllc.com

Dave Happel

Aerovance Inc.

510-549-5525

dave.happel@aerovance.com


'/>"/>
SOURCE Aerovance Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PARIs eFlow Included in Gileads NDA Submission for Aztreonam Lysine for Inhalation
2. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
3. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
4. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
5. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
6. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
7. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
8. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
9. IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
10. Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
11. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... Delcath Systems, Inc. (Nasdaq: ... its proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for ... today that Dr. James F. Pingpank will present ... Therapies, to be held February 21-23, 2009. ...
... Mass., Feb. 18 ,Abbott ( NYSE: ABT ) ... Hepatitis C (HCV) collaboration with a first-in-human study,evaluating ... of chronic,HCV. The objectives of the trial ... was discovered as part of a worldwide alliance,between ...
Cached Medicine Technology:Dr. James F. Pingpank to Present at Leading Regional Therapies Conference 2Dr. James F. Pingpank to Present at Leading Regional Therapies Conference 3Dr. James F. Pingpank to Present at Leading Regional Therapies Conference 4Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor 2Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor 3
(Date:9/1/2014)... 2014 (HealthDay News) -- You may be able to convince ... new research suggests. The study included eight overweight and ... program meant to change how people react to different foods. ... overweight and obese people who weren,t in the program. ... the study and again six months later. The scans revealed ...
(Date:9/1/2014)... Liver is the largest organ inside the human body. ... in barring itself from poisons, helps in digestion of food ... many important functions such as protein production, blood clotting and ... can affect the liver, an organ the size of a ... side of the abdomen, reducing its capabilities to perform its ...
(Date:9/1/2014)... 2014 An operating theatre or operating ... performing surgical operations. An operating room comprises a myriad ... operating room lights, imaging displays as well as integration ... Transparency Market Research, a U.S.-based market research firm, the ... 4.5 billion by 2019. , According to this ...
(Date:9/1/2014)... "Women struggle with weight gain typically ... begin as early as 15, if not earlier. ... ups and downs of hormone related weight gain. ... sizes seems to rage against the hidden and ever-present ... her 40's begin to face menopause and related changes, ...
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. 29, 2014 (HealthDay ... American aid workers successfully cured a group of monkeys infected ... The drug, ZMapp, prompted recovery in all 18 monkeys who ... five days after infection. ZMapp even cured monkeys with ... away from death, said study senior author Gary Kobinger, chief ...
Breaking Medicine News(10 mins):Health News:Train Your Brain to Choose Fruit Salad Over French Fries 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 3Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3
... pill used for nerve pain offers women relief from hot ... the 45th Annual Meeting of the American Society ... decreased hot flash severity and frequency about 20 percent more ... about the same benefit as gabapentin, an older, related drug, ...
... EffortsSAN DIEGO, May 18 The Coalition for Pulmonary ... Thoracic Society,s (ATS) International conference in San Diego, Calif. ... together the world,s leading pulmonary, critical care and sleep ... partner grant program with ATS that, to date, has ...
... the disease is no more dangerous than regular flu , , ... swine flu continue to be no worse than seasonal flu, ... higher than that seen with seasonal flu, U.S. heath officials ... that the fatality [rate] is likely a little bit higher ...
... Bulletin Board: LTUS) ("Lotus" or the "Company") a company that ... today reported its financial results for the first quarter ended,March ... Highlights and Recent Developments:, -- Diluted EPS ... million, up 258% from first quarter 2008, ...
... is time for states to suspend, rather than terminate, ... say correctional health care experts from The Miriam Hospital ... of General Internal Medicine . , Although federal ... percent of states have implemented policies that withdraw inmates, ...
... - African-American women who were younger at menarche, or the ... a history of childhood sexual abuse, according to a new ... Center. The results suggest that a history of sexual abuse ... menstrual periods before age 12 years). , The study, which ...
Cached Medicine News:Health News:Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes 2Health News:Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes 3Health News:Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes 4Health News:Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference 2Health News:Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference 3Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 2Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 3Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 4Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 5Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 6Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 7Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 8Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 9Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 10Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 11Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 12Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 13Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 2Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 3Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 4Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 5Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 6Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 7Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 8Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 9Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 10Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 11Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 12Health News:Filling the gap: The importance of Medicaid continuity for former inmates 2Health News:Study finds higher prevalence of early menarche among survivors of childhood sexual abuse 2
... IMMULITE 1000 assays are designed ... and IMMULITE 1000, continuous random ... simplicity in both design and ... found in a wide variety ...
... (DHEA-S) is the sulfate ester of DHEA, ... conversion of DHEA in adrenal and extradrenal ... secreted by the adrenal cortex, and is ... DHEA possesses relatively weak androgenic activity, which ...
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM....
Medicine Products: